The Journal, Drug Designing: Open Access publishes the highest quality scientific articles amalgamating broad range of fields including molecular modeling, clinical research and drug discovery and delivery.

Drug Designing: Open Access is a peer-reviewed and open access journal with an aim to provide rapid and reliable source of information in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide.

Health technology assessment (HTA) is a multidisciplinary process to assess the ‘added value’ of a new drug. HTA bridges the gap between scientific evidence and the decisions of policy makers. It assists in decision making by quantifying the incremental benefit of a new drug against its cost. HTAs provide high-quality information to decision makers about the clinical effectiveness, cost-effectiveness, and broader impact of drugs on society and health system. With steadily growing expenditure on prescription drugs in many OECD (The Organization for Economic Co-operation and Development) countries, health care payers are turning to HTA for evidence based reimbursement decisions . Most of the Western European countries, Australia and North America use HTA as a tool to assist in the purchasing and reimbursement decisions for approved drugs.

We publish the article related to the effects of dual diagnosis, Treatment, outcomes of the treatment. We invite different types of science communications including original research article, systematic reviews, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

Manuscripts can be published through the online link. Or to the given below Email Id.

With Regards,
Sherry Peterson 
Drug Designing: Open Access
Editorial Manager
Email: drugdesign@longdom.org
Whats App:+1-947-333-4405